Gyre Therapeutics, Inc. (GYRE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Gyre Therapeutics reported revenue of $116.6M, up 10.2% from $105.8M the year before. Net income was $9.9M (a 8.5% net margin), or $0.02 per diluted share. Gross margin was 95.4% and operating margin was 9.9%. Operating activities generated $1.0M of cash, leaving -$190,000 of free cash flow. At fiscal year end, Gyre Therapeutics held $166.1M in total assets against $23.9M in total liabilities, including $37.1M of cash and equivalents.
Open the full interactive Gyre Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Gyre Therapeutics Key Stats
| Share Price | $6.71 |
|---|---|
| Market Cap | $675.3M |
| P/E Ratio | 335.5 |
| Revenue YoY Growth | +10.2% |
| 52-Week Range | $5.56 – $8.87 |
| Shares Outstanding | 100.6 million (basic, 2026 Q2) |
Gyre Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $20.9M | $7.3M | $0 | $113.5M | $105.8M | $116.6M |
| Cost of Goods Sold | — | — | — | $4.6M | $3.9M | $5.4M |
| Gross Profit | — | — | — | $108.8M | $101.9M | $111.2M |
| Operating Income | -$57.4M | -$87.9M | -$8.6M | -$67.2M | $16.2M | $11.5M |
| Pre-Tax Income | -$56.2M | -$87.9M | -$7.9M | -$77.0M | $23.2M | $14.4M |
| Income Tax | — | — | $348,000 | $8.5M | $5.3M | $4.6M |
| Net Income | -$56.2M | -$87.9M | -$8.2M | -$85.5M | $17.9M | $9.9M |
| Diluted EPS | -$43.95 | -$43.05 | -$3.90 | -$1.41 | $0.05 | $0.02 |
Gyre Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $30.6M | $37.2M | $22.5M | $29.1M |
| Net Income | $5.9M | -$1.4M | -$9.9M | -$14.3M |
| Diluted EPS | $0.03 | -$0.01 | -$0.10 | -$0.12 |
Gyre Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.4M | $44.3M | $21.7M | $33.5M | $11.8M | $37.1M |
| Current Assets | $89.5M | $51.5M | $28.2M | $57.2M | $64.8M | $102.4M |
| Total Assets | $94.8M | $55.7M | $28.4M | $116.5M | $125.4M | $166.1M |
| Current Liabilities | $17.8M | $14.2M | $16.8M | $20.0M | $19.5M | $18.3M |
| Total Liabilities | $18.8M | $14.6M | $16.8M | $38.1M | $27.0M | $23.9M |
| Shareholders' Equity | $76.1M | $41.1M | -$21.7M | -$15.8M | $63.3M | $106.0M |
Gyre Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$55.0M | -$83.8M | -$33.1M | $25.9M | -$3.6M | $1.0M |
| Cash From Investing | $9.7M | $48.2M | $55.4M | -$19.8M | -$19.9M | -$474,000 |
| Cash From Financing | $60.4M | $49.6M | -$45.0M | $2.5M | $2.1M | $24.4M |
| Free Cash Flow | — | — | -$33.9M | $17.4M | -$5.9M | -$190,000 |
| Dividends Paid | — | — | $45.0M | — | — | — |
Figures from Gyre Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Gyre Therapeutics financials page for every line item.
Gyre Therapeutics Company Profile
| Ticker | GYRE |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer, smaller reporting company |
| SEC CIK | 0001124105 |
Frequently Asked Questions
What was Gyre Therapeutics' revenue in fiscal 2025?
Gyre Therapeutics (GYRE) reported revenue of $116.6M for fiscal 2025.
What is Gyre Therapeutics' annual revenue history?
Gyre Therapeutics' annual revenue by fiscal year: 2020: $20.9M; 2021: $7.3M; 2022: $0; 2023: $113.5M; 2024: $105.8M; 2025: $116.6M.
What was Gyre Therapeutics' net income in fiscal 2025?
Gyre Therapeutics reported net income of $9.9M for fiscal 2025.
What was Gyre Therapeutics' earnings per share (EPS) in fiscal 2025?
Gyre Therapeutics' diluted EPS was $0.02 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Gyre Therapeutics generate in fiscal 2025?
Gyre Therapeutics generated -$190,000 of free cash flow in fiscal 2025.
What was Gyre Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Gyre Therapeutics reported revenue of $29.1M.
How many shares of Gyre Therapeutics are outstanding?
Gyre Therapeutics reported a weighted average of 100.6 million basic shares outstanding in 2026 Q2.
What is Gyre Therapeutics' market cap?
Based on its latest closing price, Gyre Therapeutics (GYRE) has a market capitalization of about $675.3M.
When does Gyre Therapeutics' fiscal year end?
Gyre Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Gyre Therapeutics headquartered?
Gyre Therapeutics lists its business address in San Diego, California in its SEC filings.